156 related articles for article (PubMed ID: 37724607)
21. High Response Rates and Promising Outcomes of Patients with Relapsed Ewing Sarcoma, Especially in Adolescents and Young Adults Treated on a Novel Hybrid Salvage Chemotherapy Regimen.
Vijayasekharan K; Ramanathan S; Chinnaswamy G; Prasad M; Gulia A; Janu A; Rekhi B; Ramadwar M; Khanna N; Laskar S; Puranadare N; Bajpai J; Puri A; Banavali S; Vora T
J Adolesc Young Adult Oncol; 2021 Apr; 10(2):185-192. PubMed ID: 32706630
[No Abstract] [Full Text] [Related]
22. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.
Palmerini E; Jones RL; Setola E; Picci P; Marchesi E; Luksch R; Grignani G; Cesari M; Longhi A; Abate ME; Paioli A; Szucs Z; D'ambrosio L; Scotlandi K; Fagioli F; Asaftei S; Ferrari S
Acta Oncol; 2018 Jul; 57(7):958-964. PubMed ID: 29533113
[TBL] [Abstract][Full Text] [Related]
23. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
[TBL] [Abstract][Full Text] [Related]
24. The 'other' bone sarcomas in Japan: a retrospective study of primary bone sarcomas other than osteosarcoma, Ewing sarcoma and chondrosarcoma, using data from the Bone Tumuor Registry in Japan.
Nagano A; Tsugita M; Nishimoto Y; Akiyama H; Kawai A
Jpn J Clin Oncol; 2021 Aug; 51(9):1430-1436. PubMed ID: 34105731
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma.
Bailly C; Leforestier R; Campion L; Thebaud E; Moreau A; Kraeber-Bodere F; Carlier T; Bodet-Milin C
PLoS One; 2017; 12(8):e0183841. PubMed ID: 28841702
[TBL] [Abstract][Full Text] [Related]
26. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.
Albarrán V; Villamayor ML; Chamorro J; Rosero DI; Pozas J; San Román M; Calvo JC; Pérez de Aguado P; Moreno J; Guerrero P; González C; García de Quevedo C; Álvarez-Ballesteros P; Vaz MÁ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430263
[TBL] [Abstract][Full Text] [Related]
27. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].
Ye T; Yuan SY; Fan L; Feng LW; Chen YT; Chen J
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2435-2440. PubMed ID: 36000372
[No Abstract] [Full Text] [Related]
28. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection.
Pan HY; Morani A; Wang WL; Hess KR; Paulino AC; Ludwig JA; Lin PP; Daw NC; Mahajan A
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):349-57. PubMed ID: 25772182
[TBL] [Abstract][Full Text] [Related]
30. Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma.
Boyce-Fappiano D; Guadagnolo BA; Ratan R; Wang WL; Wagner MJ; Patel S; Livingston JA; Lin PP; Diao K; Mitra D; Farooqi A; Lazar AJ; Roland CL; Bishop AJ
Oncologist; 2021 Mar; 26(3):250-260. PubMed ID: 33289298
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.
Merimsky O; Meller I; Flusser G; Kollender Y; Issakov J; Weil-Ben-Arush M; Fenig E; Neuman G; Sapir D; Ariad S; Inbar M
Cancer Chemother Pharmacol; 2000; 45(2):177-81. PubMed ID: 10663634
[TBL] [Abstract][Full Text] [Related]
32. Distribution and Surgical Management of Visceral Ewing Sarcoma Among Children and Adolescents.
Wallace MW; Niec JA; Ghani MOA; McKay KG; Idrees K; Liang J; Borinstein SC; Lovvorn HN
J Pediatr Surg; 2023 Sep; 58(9):1727-1735. PubMed ID: 36774201
[TBL] [Abstract][Full Text] [Related]
33. Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study.
Ribeiro MF; Peretz Soroka H; Bhura Z; Hirsch I; Wunder J; Ferguson P; Tsoi K; Brar S; Gladdy R; Swallow C; Chung P; Catton C; Wong P; Watson G; Razak ARA; Gupta AA; Shultz D
Ther Adv Med Oncol; 2023; 15():17588359231198943. PubMed ID: 37781501
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of factors affecting survival rate in primary bone sarcomas with extremity and pelvis involvement.
Sofulu Ö; Erol B
Acta Orthop Traumatol Turc; 2020 May; 54(3):234-244. PubMed ID: 32544060
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A single-institution retrospective analysis.
Sugiyama M; Arakawa A; Shirakawa N; Tao K; Tanimura K; Nakajima M; Watanabe Y; Kumamoto T; Maniwa J; Yoneda A; Iwata S; Kobayashi E; Kawai A; Ogawa C
Pediatr Blood Cancer; 2023 Jul; 70(7):e30360. PubMed ID: 37073613
[TBL] [Abstract][Full Text] [Related]
37. Regorafenib for the Treatment of Sarcoma.
Blay JY; Duffaud F; George S; Maki RG; Penel N
Curr Treat Options Oncol; 2022 Nov; 23(11):1477-1502. PubMed ID: 36178573
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
[TBL] [Abstract][Full Text] [Related]
39. Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan.
Fukushima T; Ogura K; Akiyama T; Takeshita K; Kawai A
BMC Musculoskelet Disord; 2018 Aug; 19(1):297. PubMed ID: 30121085
[TBL] [Abstract][Full Text] [Related]
40. EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Giordano G; Merlini A; Ferrero G; Mesiano G; Fiorino E; Brusco S; Centomo ML; Leuci V; D'Ambrosio L; Aglietta M; Sangiolo D; Grignani G; Pignochino Y
Cells; 2021 Oct; 10(11):. PubMed ID: 34831119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
